-
10 batches of non-essential drugs in Yunnan Province were suspended from trading, 21 pharmaceutical companies applied for price cuts
Time of Update: 2022-05-02
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued two announcements, namely, “Announcement on the Qualification of Non-essential Drugs to Stop Trading” and “Announcement on Enterprises Applying for Price Reduction” .
, Ltd. In addition, after sorting out, the Yunnan Provincial Government Procurement Center received information from Shanghai Huilun Jiangsu Pharmaceutical Co.
-
CD30-targeted drug Adcetris combined with chemotherapy: first-line treatment significantly prolongs survival!
Time of Update: 2022-05-02
ECHELON-1 is a randomized, open-label, international phase 3 study in adults with newly diagnosed advanced (stage III or IV) cHL to compare Adcetris combined with chemotherapy AVD (doxorubicin + vincristine) Efficacy and safety of ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) relative to the currently accepted standard-of-care regimen ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) .
-
Discuss the future development of "Nobel Prize-blockbuster tumor drugs" from the perspective of clinical value
Time of Update: 2022-05-02
Here, the author takes the "Zomib" family, a key drug for multiple myeloma, as an example to discuss the real clinical value of tumor drugs with colleagues in the industry, and at the same time discuss the future development trend of proteasome inhibitors .
-
Lai Mei Pharmaceutical was sued again for impotence "magic medicine" triggering a series of cases
Time of Update: 2022-05-02
Haiyue Pharmaceutical announced in August 2020 that the company stated in the "Purchase and Sales Contract" that it would give Tadalafil Tablets (Xinweige) experience packs at a ratio of 1:1 based on the number of deliveries from Lai Mei Pharmaceutical.
-
The results of the sixth batch of national mining will be implemented in May, and the market of 25 billion may bring about great changes
Time of Update: 2022-05-02
Following the announcement of the results of the sixth batch of national procurement, local pharmaceutical companies such as Gan & Lee Pharmaceuticals, Tonghua Dongbao, and United Laboratories, which won the bid, also issued announcements stating that winning the bid for centralized procurement will help expand the sales of related products and increase the company's product market share.
-
4 domestic pharmaceutical companies released 2021 performance reports, 2 reported good news
Time of Update: 2022-05-02
61% over the same period last year; the net profit attributable to shareholders of the parent company is 171 million yuan, an increase of 77.
Jing Pharmaceutical's 2021 annual performance bulletin shows that during the reporting period, the company achieved operating income of 201 million yuan, a year-on-year increase of 627.
-
Legend Bio's cilta-cel has been approved by the FDA for the launch of domestic CAR-T target competition
Time of Update: 2022-05-02
Among them, the autologous CD4-targeted CAR-T therapy LB1901 has passed the FDA's IND application and has started a phase I clinical trial in the United States for the treatment of adult relapsed or refractory peripheral T-cell lymphoma (PTCL) or skin T cells Lymphoma (PTCL), a product with rapid development in Legend Bio's pipeline .
-
Ge Lei, Securities Representative of Watson Pharmaceuticals, resigns
Time of Update: 2022-05-02
On February 22, Watson Pharmaceuticals issued an announcement stating that Ge Lei resigned from the position of the company's securities affairs representative due to personal reasons.
The resignation letter took effect from the day it was served on the company's board of directors .
-
What safety data support is needed for the clinical advancement of innovative drugs?
Time of Update: 2022-05-02
0101Nonclinical safety studies required for marketing approvalNonclinical safety studies required for marketing approvalAccording to the ICH guideline - "Guideline M3(R2) for Non-clinical Safety Research Supporting Drugs for Clinical Trials and Marketing", the non-clinical safety tests required for drug marketing approval usually include: pharmacology tests, general toxicology tests , toxicokinetics and non-clinical pharmacokinetics tests, reproductive toxicity tests, genotoxicity tests, and drugs with special reasons for concern or intended for long-term use, carcinogenicity tests are also required .
-
How many hurdles does the internationalization of Chinese pharmaceutical companies need to pass?
Time of Update: 2022-05-02
The measures include supporting enterprises to carry out simultaneous registration of innovative drugs at home and abroad, and conducting global multi-center clinical research for developed country markets.
Domestic Me-better innovative drug companies also need to consider the intellectual property rights of their products when they internationalize .
-
Huadong Medicine's wholly-owned subsidiary signed an equity investment agreement with Heidelberg Pharma
Time of Update: 2022-05-02
On February 28, Huadong Medicine announced that its wholly-owned subsidiary signed an equity investment agreement with Heidelberg Pharma in Germany and obtained an exclusive license agreement for the company's products .
, a wholly-owned subsidiary of the company, has reached an exclusive product license agreement with Heidelberg Pharma.
-
The pharmaceutical market is booming!
Time of Update: 2022-05-02
. It is reported that since the beginning of the year, a large number of pharmaceutical companies, including Ruikang Pharmaceutical, Yunnan Baiyao, and Xianju Pharmaceutical, have announced that they will divest their assets .
On January 19, Ruikang Pharmaceutical announced that the company planned to transfer 51% of Honglin Pharmaceuticals shares, and Wang Hongliang took over .
-
25 listed pharmaceutical and biological companies disclosed their 2021 performance reports
Time of Update: 2022-05-02
From the perspective of revenue, 4 of the 25 listed pharmaceutical and biological companies have a revenue of over 10 billion yuan, namely Kelun Pharmaceutical, Sinopharm Hyundai, Zhifei Bio, and WuXi AppTec .
-
Sinopharm Modern Nifedipine Controlled-Release Tablets and Omeprazole Enteric-Coated Tablets Pass the Consistency Evaluation of Generic Drugs
Time of Update: 2022-05-02
The sales revenue of the company's nifedipine controlled-release tablets in 2020 is approximately RMB 1.
According to the CDE website, the companies that have passed or are deemed to have passed the consistency evaluation of nifedipine controlled-release tablets include Beijing Honglin Pharmaceutical Co.
-
Kelun Pharmaceutical Holdings subsidiary SKB378/HBM9378 injection obtained clinical trial notice
Time of Update: 2022-05-02
On February 21, Kelun Pharmaceutical issued an announcement saying that the SKB378/HBM9378 injection jointly developed by its holding subsidiary Kelun Botai and Hebo Pharmaceutical obtained the clinical trial notice from the State Drug Administration, agreeing to carry out moderate-to-severe clinical trials for this product.
-
In February, the pharmaceutical and biological companies were investigated by institutions, and the number of 3 reception fund companies exceeded 30
Time of Update: 2022-05-02
The record form of investor relations activities disclosed by Changchun Hi-Tech on February 21 shows that 145 institutional investors including Broadway Fund and Bosera Fund investigated the company on February 18.
-
CStone Receives New $2 Billion Varieties for 4 Consecutive Years
Time of Update: 2022-05-02
On February 17, CStone announced that the new drug application for pratinib has been accepted in Taiwan, China, the drug is mainly used for the treatment of locally advanced or metastatic non-small c
-
Shanghai Suspends Xinfeng Pharmaceutical's Procurement Qualification for Luotongding Sulfate Injection for 1 Year
Time of Update: 2022-05-02
On February 24, 2022, the Shanghai Pharmaceutical Centralized Tendering and Procurement Administration issued a notice on the suspension of the procurement qualification of Luotongdine Sulfate Injection produced by Guangdong Xinfeng Pharmaceutical Co.
51), the procurement qualification of Luotongding Sulfate Injection produced by Guangdong Xinfeng Pharmaceutical Co.
-
Kangchen Pharmaceutical's KC1036 entered Phase Ib/II clinical study for the treatment of advanced digestive system tumors
Time of Update: 2022-05-02
On February 23, Kangchen Pharmaceutical issued an announcement saying that recently, Kangchen Pharmaceutical's "Phase Ib/II clinical study plan to evaluate the efficacy and safety of KC1036 in the treatment of advanced recurrent or metastatic digestive system tumors" was published in the Chinese Academy of Medical Sciences.
-
Kexing Pharmaceutical's 2021 performance: total revenue of 1.285 billion yuan, a year-on-year increase of 5.31%
Time of Update: 2022-05-02
285 billion yuan in 2021, a year-on-year increase of 5.
31%; net profit attributable to owners of the parent company is 90 million yuan, a year-on-year decrease of 35.
45 yuan, a year-on-year decrease of 51.
83%, a year-on-year decrease of 13.
